Combination of BKM120 and Capmatinib (INC280), a c-Met inhibitor, is investigated in a phase Ib/II clinical trials to assess its safety, dose and anti-tumor activity in patients with recurrent GBM with PTEN loss or MET alteration (NCT01870726). The gene discussed is PTEN; the disease is glioblastoma.